Literature DB >> 12361192

N-acetylcysteine potentiates the antihypertensive effect of ACE inhibitors in hypertensive patients.

Vivencio Barrios1, Alberto Calderón, Josefa Navarro-Cid, Vicente Lahera, Luis M Ruilope.   

Abstract

Sulfhydryl group donors, such as N-acetylcysteine (NAC), may enhance the antihypertensive effect of some drugs through a nitric oxide (NO) mechanism. It has been observed that the hypotensive effect of angiotensin-converting enzyme inhibitors (ACEIs) is, at least partially, mediated by NO. We performed a within patient crossover study with the aim to investigate the potential effect of NAC on the ACEI antihypertensive action, via an NO-dependent mechanism. We studied 18 smoker (> 10 years of habit and > 10 cigarettes daily) hypertensive patients (15 males and three females, aged 69 +/- 5 years) on ACEI therapy (11 captopril and seven enalapril). Patients were randomly allocated to two treatment arms. In one arm, the patients (n = 10) initially received the addition of NAC (600 mg t.i.d.) to the ACEI regimen. In the other group (n = 8), the patients remained only on ACEI. After 21 days, the therapeutic patterns were crossed. The first group received only ACEI, and the second group received ACEI and NAC and completed other 21-day treatment period. We evaluate the effect of NAC on each patient by ambulatory blood pressure monitoring (ABPM), performed at the end of each therapeutic regimen. A significant decrease in systolic and diastolic 24-h blood pressure (24 hBP) and daytime BP (dtBP) was achieved with the combination of ACEI and NAC (ACEI + NAC) when compared to the period with only ACEI: 24 hBP = 146.1 +/- 4.2 vs 137 +/- 3.1 (p < 0.05) and 89.2 +/- 2.8 vs 83.5 +/- 3.7mmHg (p = 0.01). DtBP: 149.7 +/- 5.6 vs 141 +/- 3.7 and 92.1 +/- 4 vs 86 +/- 3.2 (both, p < 0.05). No significant difference was observed in night-time BP (ntBP). The NAC effect was not statistically different for the two ACEIs. In conclusion, the addition of NAC to an ACEI potentiates its antihypertensive effect during 24hBP and dtBP in smoker hypertensives. This effect may be mediated by an NO-dependent mechanism, probably through the protective effect of NAC on NO oxidation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12361192     DOI: 10.1080/08037050213760

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  9 in total

1.  The antihypertensive effect of cysteine.

Authors:  Sudesh Vasdev; Pawan Singal; Vicki Gill
Journal:  Int J Angiol       Date:  2009

2.  Antihypertensive effects of dietary protein and its mechanism.

Authors:  Sudesh Vasdev; Jennifer Stuckless
Journal:  Int J Angiol       Date:  2010

Review 3.  Essential hypertension and oxidative stress: New insights.

Authors:  Jaime González; Nicolás Valls; Roberto Brito; Ramón Rodrigo
Journal:  World J Cardiol       Date:  2014-06-26

Review 4.  An increased need for dietary cysteine in support of glutathione synthesis may underlie the increased risk for mortality associated with low protein intake in the elderly.

Authors:  Mark F McCarty; James J DiNicolantonio
Journal:  Age (Dordr)       Date:  2015-09-11

Review 5.  Vascular endothelial dysfunction and pharmacological treatment.

Authors:  Jin Bo Su
Journal:  World J Cardiol       Date:  2015-11-26

Review 6.  Beneficial effect of low ethanol intake on the cardiovascular system: possible biochemical mechanisms.

Authors:  Sudesh Vasdev; Vicki Gill; Pawan K Singal
Journal:  Vasc Health Risk Manag       Date:  2006

7.  Comparison of N-acetylcysteine and angiotensin converting enzyme inhibitors in blood pressure regulation in hypertensive patients.

Authors:  Arsalan Khaledifar; Mahmoud Mobasheri; Soleiman Kheiri; Zeinab Zamani
Journal:  ARYA Atheroscler       Date:  2015-01

Review 8.  NADPH Oxidase Activity in Cerebral Arterioles Is a Key Mediator of Cerebral Small Vessel Disease-Implications for Prevention.

Authors:  Mark F McCarty
Journal:  Healthcare (Basel)       Date:  2015-04-15

9.  CU06-1004 enhances vascular integrity and improves cardiac remodeling by suppressing edema and inflammation in myocardial ischemia-reperfusion injury.

Authors:  Haiying Zhang; Hyeok Kim; Bong Woo Park; Minyoung Noh; Yeomyeong Kim; Jeongeun Park; Jae-Hyun Park; Jin-Ju Kim; Woo-Sup Sim; Kiwon Ban; Hun-Jun Park; Young-Guen Kwon
Journal:  Exp Mol Med       Date:  2022-01-07       Impact factor: 12.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.